Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
T Karagiannis, P Boura… - Therapeutic advances in …, 2014 - journals.sagepub.com
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral
antihyperglycemic agent that enhance insulin secretion by reducing degradation of …
antihyperglycemic agent that enhance insulin secretion by reducing degradation of …
[HTML][HTML] Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios
F Gomez-Peralta, C Abreu, S Gomez-Rodriguez… - Diabetes Therapy, 2018 - Springer
The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in
combination with other oral antidiabetic agents or basal insulin are well established. DPP4 …
combination with other oral antidiabetic agents or basal insulin are well established. DPP4 …
Mechanism of action of DPP-4 inhibitors—new insights
A Vella - The Journal of Clinical Endocrinology & Metabolism, 2012 - academic.oup.com
Glucagon-like peptide-1 (GLP-1) is an incretin hor-mone that results in glucose-dependent
insulin secretion, suppression of glucagon secretion, a delay in gastric emptying, and a …
insulin secretion, suppression of glucagon secretion, a delay in gastric emptying, and a …
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials
MB Rehman, BV Tudrej, J Soustre, M Buisson… - Diabetes & …, 2017 - Elsevier
Background Guidelines for type 2 diabetes (T2D) recommend reducing HbA 1c through
lifestyle interventions and glucose-lowering drugs (metformin, then combination with …
lifestyle interventions and glucose-lowering drugs (metformin, then combination with …
[HTML][HTML] Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism
B Ahrén, JE Foley - Diabetologia, 2016 - Springer
Inhibition of dipeptidyl peptidase-4 (DPP-4) is an established glucose-lowering strategy for
the management of type 2 diabetes mellitus. DPP-4 inhibitors reduce both fasting and …
the management of type 2 diabetes mellitus. DPP-4 inhibitors reduce both fasting and …
Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
Background Both sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl
peptidase‐4 (DPP4) inhibitors can be used to treat patients with type 2 diabetes mellitus …
peptidase‐4 (DPP4) inhibitors can be used to treat patients with type 2 diabetes mellitus …
Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
CF Deacon, HE Lebovitz - Diabetes, Obesity and Metabolism, 2016 - Wiley Online Library
Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent
does not generally provide durable glycaemic control over the long term. Sulphonylurea …
does not generally provide durable glycaemic control over the long term. Sulphonylurea …
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M Monami, I Iacomelli, N Marchionni… - Nutrition, Metabolism and …, 2010 - Elsevier
BACKGROUND AND AIM: The role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the
treatment of type 2 diabetes is debated; many recent trials, which were not included in …
treatment of type 2 diabetes is debated; many recent trials, which were not included in …
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
CF Deacon, JJ Holst - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: Dipeptidyl peptidase (DPP)-4 inhibitors belong to one class of drugs that have
been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions …
been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions …
Novel combination treatment of type 2 diabetes DPP-4 inhibition+ metformin
B Ahren - Vascular health and risk management, 2008 - Taylor & Francis
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based
on prevention of the inactivation process of bioactive peptides, the most important in the …
on prevention of the inactivation process of bioactive peptides, the most important in the …